ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL
Published: 30/09/21, 10:34am (AEST)•3 pages